Executive Leadership Team

PROF. CHRIS WOOD is Chairman and Group Executive Director.
read more

Chris founded the business and led the Group’s research and development program that is at the heart of the Group’s core technology. Chris has more than 20 years of experience in the biotechnology sector, having founded, managed and successfully exited four companies including Bioenvision and Medirace. Prior to this Chris was a consultant surgeon at the Royal Postgraduate Medical School. Chris is Executive Chairman of Medannex Limited and Oncobiopharm Limited, and a Non-Executive Director of MiNA Therapeutics.

JUSTIN BARNES is Group Executive Director and co-heads the Executive Leadership Team.

read more

Justin was instrumental in the development of Thirty’s core technology and brings to the Group a successful 30-year track record in the Healthcare industry. During this time Justin has built and sold several international companies, each with global research, development, manufacturing and sales organisations. Justin is also a Non-Executive Director of Rayner Surgical Group, an advisor to several early-stage companies, and a partner in a healthcare VC firm. Prior to his business career, Justin was a soldier in the British Army.

SYD HANNA is Group Executive Director and co-heads the Executive Leadership Team.

read more
Syd joined the predecessor to Thirty, Edixomed in 2012 and led the business’s growth, strategy, financing and research program and the creation of Thirty Group. Syd has extensive experience founding and building business for long term value with private and institutional backing across the drug discovery, medical device and service sectors. Syd is on the advisory board of several early stage biopharmaceutical companies, serves as an Executive Director of Medannex and OncoBioPharm Limited and is a Chartered Global Management Accountant.

KEITH LIPMAN is Group Executive Director.

read more

Keith chairs the Scientific Advisory Committee. Keith is the lead private investor in the business since 2012. He is an investor in, and advisor to, companies principally in the data and scientific fields. Keith earned his PhD in Astrophysics from Cambridge University in 1992. He was a founder of a group of companies created to use scientific research to design algorithms to predict the future movements of financial securities. This proprietary firm was one of the largest trading firms in the financial markets.

DR. VICKIE R DRIVER is Executive Vice President and Global Head of Regenerative Medicine.

read more
Vickie joined Thirty’s Executive Leadership in 2019. Vickie’s medical and scientific career has long had a special emphasis on tissue repair, regeneration and preventing limb loss. As a board-certified Podiatric Surgeon also certified in wound care and with research as well as clinical expertise, she is an outspoken ambassador for progressive scientific change that will directly benefit improving care to patients. Vickie previously held the positions of Director, Translational Medicine at Novartis, Professor of Orthopedic Surgery at Brown University (Clin), and Associate Professor of Surgery at Boston University. She serves as a board member for international medical societies, academic initiatives and private companies. She is a Fellow of the American College of Foot and Ankle Surgeons (USA) and Fellow, Royal College of Physicians and Surgeons-PM (Glasgow).
DR. ANDY WEYMANN is Senior Medical Advisor.
read more
Andy joined Thirty’s Executive Leadership in 2020. Immediately prior to joining Thirty, Andy was Chief Medical Officer for Smith & Nephew, where he provided global leadership and oversight of Clinical, Scientific and Medical Affairs with accountability for patient and product safely. He was also a Board Member of S&N Switzerland and a Board Member of Actracsys, a company acquired by S&N. Prior to his corporate career, Andy was a physician in Switzerland practising in trauma and orthopaedic surgery, having obtained his Masters in Human Medicine at the University of Zurich, Switzerland. Following his time as a Medical Doctor, Andy completed his MBA degree at the Graduate School of Business, University of Rochester.

30 TECHNOLOGY Therapeutic Nitric Oxide